Literature DB >> 2645902

Hemolytic uremic syndrome.

M Levin1, M D Walters, T M Barratt.   

Abstract

HUS has now emerged as a common clinical and pathologic syndrome that may result from a variety of disease processes. On the basis of clinical and epidemiologic criteria, several distinct subgroups of the disorder have been distinguished, the most common of which are the result of infectious processes, whereas the rarer forms may be genetically determined or acquired defects in vascular homeostasis. A related group of bacterial toxins, verotoxins, and Shiga toxin, produced by a variety of species of enteric pathogens, have been implicated in the pathogenesis of typical childhood HUS. In the few years since verotoxin-producing organisms were first incriminated as the possible etiologic agents of HUS, there has been a remarkable growth in knowledge of the biology of verotoxin and its role, not only in HUS but in hemorrhagic colitis and childhood diarrhea. The availability of purified toxin and new tools for detection of verotoxin and verotoxin-producing organisms, such as monoclonal antibodies and probes for DNA hybridization, should enable definitive studies of the epidemiology and pathogenesis of verotoxin-associated HUS to be undertaken. The growing understanding of HUS should eventually lead to improved treatment and ultimately to prevention of this serious childhood disorder.

Entities:  

Mesh:

Year:  1989        PMID: 2645902

Source DB:  PubMed          Journal:  Adv Pediatr Infect Dis        ISSN: 0884-9404


  16 in total

1.  A plea for standardized terminology within the haemolytic uraemic syndromes.

Authors:  C M Taylor; D V Milford; R H White
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

2.  Report from the British Paediatric Surveillance Unit.

Authors:  S M Hall; M Glickman
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

3.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria.

Authors:  S L Schulman; B S Kaplan
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

5.  The serological relationship between Escherichia coli O157 and Yersinia enterocolitica O9 using sera from patients with brucellosis.

Authors:  H Chart; O A Okubadejo; B Rowe
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

6.  The serological relationship between Yersinia enterocolitica O9 and Escherichia coli O157 using sera from patients with yersiniosis and haemolytic uraemic syndrome.

Authors:  H Chart; T Cheasty; D Cope; R J Gross; B Rowe
Journal:  Epidemiol Infect       Date:  1991-10       Impact factor: 2.451

7.  Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model.

Authors:  S W Lindgren; A R Melton; A D O'Brien
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection.

Authors:  D G de Silva; L N Mendis; N Sheron; G J Alexander; D C Candy; H Chart; B Rowe
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

9.  Diarrhoea in close contacts as a risk factor for childhood haemolytic uraemic syndrome. The CPKDRC co-investigators.

Authors:  P C Rowe; E Orrbine; H Lior; G A Wells; P N McLaine
Journal:  Epidemiol Infect       Date:  1993-02       Impact factor: 2.451

10.  Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2.

Authors:  H Chart; D Law; B Rowe; D W Acheson
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.